Live Feeds
● LIVE Updated 52m ago · 16 sources tracked

Retatrutide beats Ozempic on weight loss, blood sugar control, study says

Eli Lilly's experimental drug retatrutide showed greater weight loss and improved blood sugar control compared to Novo's Ozempic in a head-to-head trial. Retatrutide helped patients lose more than twice as much weight as Ozempic's highest approved dose. The study's results support a regulatory application expected in the first quarter of 2027.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (16)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Retatrutide provided more than double the weight loss of Ozempic's highest approved dose.
  • ✓ Retatrutide showed greater A1C reduction compared to Ozempic.
  • ✓ Eli Lilly's retatrutide is expected to support a regulatory application in the first quarter of 2027.
🛡️ Source Corroboration: 16 independent reporting domains (85% confidence) ⏱ Read time: ~2 min

What changed

The study's results were made public, showing retatrutide's superiority over Ozempic in weight loss and blood sugar control.

Live updates

  1. Retatrutide outperforms Ozempic in weight loss, blood sugar control study

    Eli Lilly's experimental drug retatrutide showed greater weight loss and improved blood sugar control compared to Novo's Ozempic in a head-to-head trial. Retatrutide helped patients lose more than twice as much weight as Ozempic's highest approved dose. The study's results support a regulatory application expected in the first quarter of 2027.

    Why it matters

    The study compared retatrutide, a triple-G drug, with Ozempic, a popular diabetes medication also used for weight loss. The results have significant implications for the obesity and diabetes treatment markets. Lilly's retatrutide is being positioned as a potential competitor to Novo's Ozempic and other weight loss medications.

    What is confirmed

    • Retatrutide provided more than double the weight loss of Ozempic's highest approved dose.
    • Retatrutide showed greater A1C reduction compared to Ozempic.
    • Eli Lilly's retatrutide is expected to support a regulatory application in the first quarter of 2027.

    What to watch next

    • Regulatory approval for retatrutide in the first quarter of 2027
    • Market availability and pricing of retatrutide
    • Comparative studies with other weight loss medications
    Sources used for this update (16)
    1. www.yahoo.com — Yahoo
    2. ABC News - Breaking News, Latest News and Videos — New weight loss drug retatrutide provides double the weight loss of Ozempic, Lilly says
    3. Reuters — Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trial
    4. STAT — Lilly’s triple-G drug beats Ozempic in head-to-head study
    5. Fierce Biotech — Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
    6. www.biospace.com — Lilly’s retatrutide trounces Novo’s Ozempic in diabetes ...
    7. nypost.com — Retatrutide delivers double the weight loss as Ozempic: study
    8. USA Today — Retatrutide beats Ozempic on weight loss, blood sugar control, study says
    9. KHOU — Eli Lilly says retatrutide shows more weight loss compared to Ozempic
    10. BioPharma Dive — Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
    11. PR Newswire — Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
    12. www.wkyc.com — At least 30 killed in crash between 2 trains in Spain, according to media reports
    confidence 85%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community